KRAS and non-small cell lung carcinoma: While monotherapy with KRAS G12C inhibitors has shown a moderate effect in CRC, especially compared to their efficacy in other cancers such as non-small-cell lung cancer, combination treatments are increasingly recognized to overcome treatment resistance and improve outcomes.